Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0WGZXJ
ADC Name
F8-TNF
Synonyms
F8 TNF
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Colon cancer [ICD11:2B90]
Investigative
Antibody Name
scFv(F8) Anti-ody
  Antibody Info 
Antigen Name
T-cell surface glycoprotein CD8 alpha chain (CD8A); T-cell surface glycoprotein CD8 alpha chain (CD8A)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 86.7
%
CT26 cells
Colon carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 86.70% (Day 21) Moderate CD8 expression (CD8 ++)
Method Description
CT26 Cells were implanted subcutaneously (s.c.) in the right flank of the mice using 3x106 cells per animal. Mice received three injections of either 1 g F8-TNF (WEHI-164 tumor-bearing mice) or 2.5 g (CT26 tumor-bearing mice) every 48 h starting on the day after vaccination.
In Vivo Model CT26 CDX model
In Vitro Model Colon carcinoma CT26 cells CVCL_7254
References
Ref 1 Antibody-based Delivery of TNF to the Tumor Neovasculature Potentiates the Therapeutic Activity of a Peptide Anticancer Vaccine. Clin Cancer Res. 2019 Jan 15;25(2):698-709. doi: 10.1158/1078-0432.CCR-18-1728. Epub 2018 Oct 16.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.